Bioconjugation creates essential reagents for vaccines, immunogens and diagnostics. We have decades of experience in conjugate vaccines and proprietary chemistry for preparing carbohydrate conjugate vaccines. FinaBio scientists are experts in the design and synthesis of conjugate vaccines, linking proteins to antigens (polysaccharides, oligosaccharides, peptides and haptens).
Andrew Lees, PhD, Scientific Director, is a leader in the field of conjugate vaccine chemistry. He is known for his introduction of the widely used CDAP chemistry for the synthesis of conjugate vaccines.1,2. FinaBio also offers proprietary methods for high yield reductive amination conjugation based on oxime chemistry3, a superior alternative to the widely used reductive amination.
Bioconjugation specialties include:
- Conjugate vaccines
- Biotinylation and fluorescent labeling
- Antibody-enzyme and other protein-protein conjugates
- Peptide immunogens
Our Conjugate Vaccine Services include:
- Research and development
- Training client scientists
- Supporting implementation at the client’s site
- Lees et al. Activation of soluble polysaccharides with 1-cyano-4- dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190, 1995.
- Shafer et al. Activation of soluble polysaccharides with CDAP for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine. 18:1273, 2000.
- Lopez-Acosta et al. Versatile and efficient synthesis of protein–polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine, 24:716, 2006.